In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Feature|Articles|January 30, 2026
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
Author(s)Kyle Doherty
Fact checked by: Chris Ryan
OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.
Advertisement
Advertisement
Over the course of 2025, clinical trial data presented during major medical meetings across lung and gynecologic cancers, as well as hematologic malignancies, made major waves. Notable advances included the emergence of relacorilant (CORT125134) in platinum-resistant ovarian cancer (PROC), the confirmation of the role of tarlatamab-dlle (Imdelltra) in extensive-stage small cell lung cancer (ES-SCLC), and event-free survival (EFS) improvement with venetoclax (Venclexta) plus a hypomethylating agent (HMA) in induction-eligible acute myeloid leukemia (AML).
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Advertisement
Advertisement